The government is encouraging dermatologists to prescribe cheaper biosimilar brands of infliximab by introducing less restrictive PBS Authority criteria. From 1 January 2019 the biosimilars uptake driver policy has been applied to Inflectra and Renflexis biosimilar brands of infliximab listed on the PBS to compete with the reference biological medicine Remicade in the treatment of ...
PBS eases infliximab restrictions to encourage use of biosimilars in psoriasis
By Michael Woodhead
7 Feb 2019